Heather S L Jim1, Kelly A Hyland2, Ashley M Nelson2, Javier Pinilla-Ibarz3, Kendra Sweet3, Marieke Gielissen4,5, Hailey Bulls1, Aasha I Hoogland1, Paul B Jacobsen6, Hans Knoop4. 1. Department of Health Outcomes and Behavior, Moffitt Cancer Center, Tampa, Florida. 2. Department of Psychology, University of South Florida, Tampa, Florida. 3. Department of Malignant Hematology, Moffitt Cancer Center, Tampa, Florida. 4. Department of Medical Psychology, Amsterdam University Medical Centers, University of Amsterdam, Amsterdam, the Netherlands. 5. Academy Het Dorp, Arnhem, the Netherlands. 6. Healthcare Delivery Research Program, National Cancer Institute, Bethesda, Maryland.
Abstract
BACKGROUND: Fatigue is a common and disabling side effect of targeted therapies such as tyrosine kinase inhibitors (TKIs) used to treat chronic myeloid leukemia (CML). The goal of the current study was to conduct a pilot randomized trial of the first cognitive behavioral intervention developed for fatigue due to targeted therapy. METHODS:Patients with CML treated with a TKI who were reporting moderate to severe fatigue were recruited and randomized 2:1 to cognitive behavioral therapy for targeted therapy-related fatigue (CBT-TTF) delivered via FaceTime for the iPad or to a waitlist control (WLC) group. The outcomes were acceptability, feasibility, and preliminary efficacy for fatigue (Functional Assessment of Chronic Illness Therapy-Fatigue; primary outcome) and quality of life (Functional Assessment of Cancer Therapy-General; secondary outcome). Participants were assessed before randomization and after treatment (ie, approximately 18 weeks later). RESULTS: A total of 44 patients (mean age, 55 years; 48% female) were assigned to CBT-TTF (n = 29) or WLC (n = 15). The study participation rate was 59%. Among the patients assigned to CBT-TTF, 79% completed the intervention. Intent-to-treat analyses indicated that patients assigned to CBT-TTF demonstrated greater improvements in fatigue (d = 1.06; P < .001) and overall quality of life (d = 1.15; P = .005) than those assigned to WLC. More patients randomized to CBT-TTF than WLC demonstrated clinically significant improvements in fatigue (85% vs 29%) and quality of life (88% vs 54%; P values ≤ .016). CONCLUSIONS: CBT-TTF displays preliminary efficacy in improving fatigue and quality of life among fatigued patients with CML treated with TKIs. The findings suggest that a larger randomized study is warranted.
RCT Entities:
BACKGROUND:Fatigue is a common and disabling side effect of targeted therapies such as tyrosine kinase inhibitors (TKIs) used to treat chronic myeloid leukemia (CML). The goal of the current study was to conduct a pilot randomized trial of the first cognitive behavioral intervention developed for fatigue due to targeted therapy. METHODS:Patients with CML treated with a TKI who were reporting moderate to severe fatigue were recruited and randomized 2:1 to cognitive behavioral therapy for targeted therapy-related fatigue (CBT-TTF) delivered via FaceTime for the iPad or to a waitlist control (WLC) group. The outcomes were acceptability, feasibility, and preliminary efficacy for fatigue (Functional Assessment of Chronic Illness Therapy-Fatigue; primary outcome) and quality of life (Functional Assessment of Cancer Therapy-General; secondary outcome). Participants were assessed before randomization and after treatment (ie, approximately 18 weeks later). RESULTS: A total of 44 patients (mean age, 55 years; 48% female) were assigned to CBT-TTF (n = 29) or WLC (n = 15). The study participation rate was 59%. Among the patients assigned to CBT-TTF, 79% completed the intervention. Intent-to-treat analyses indicated that patients assigned to CBT-TTF demonstrated greater improvements in fatigue (d = 1.06; P < .001) and overall quality of life (d = 1.15; P = .005) than those assigned to WLC. More patients randomized to CBT-TTF than WLC demonstrated clinically significant improvements in fatigue (85% vs 29%) and quality of life (88% vs 54%; P values ≤ .016). CONCLUSIONS: CBT-TTF displays preliminary efficacy in improving fatigue and quality of life among fatiguedpatients with CML treated with TKIs. The findings suggest that a larger randomized study is warranted.
Authors: Loretta A Williams; Araceli G Garcia Gonzalez; Patricia Ault; Tito R Mendoza; Mary L Sailors; Janet L Williams; Furong Huang; Aziz Nazha; Hagop M Kantarjian; Charles S Cleeland; Jorge E Cortes Journal: Blood Date: 2013-06-18 Impact factor: 22.113
Authors: Harriët J G Abrahams; Marieke F M Gielissen; Rogier R T Donders; Martine M Goedendorp; Agnes J van der Wouw; Constans A H H V M Verhagen; Hans Knoop Journal: Cancer Date: 2017-06-16 Impact factor: 6.860
Authors: D M Hann; P B Jacobsen; L M Azzarello; S C Martin; S L Curran; K K Fields; H Greenberg; G Lyman Journal: Qual Life Res Date: 1998-05 Impact factor: 4.147
Authors: Sarah Acaster; Rene Dickerhoof; Kendra DeBusk; Kristine Bernard; William Strauss; Lee F Allen Journal: Health Qual Life Outcomes Date: 2015-05-17 Impact factor: 3.186
Authors: Anna Cox; Grace Lucas; Afrodita Marcu; Marianne Piano; Wendy Grosvenor; Freda Mold; Roma Maguire; Emma Ream Journal: J Med Internet Res Date: 2017-01-09 Impact factor: 5.428
Authors: Frank J Penedo; Laura B Oswald; Joshua P Kronenfeld; Sofia F Garcia; David Cella; Betina Yanez Journal: Lancet Oncol Date: 2020-05 Impact factor: 41.316
Authors: Alix G Sleight; Sylvia L Crowder; Jacek Skarbinski; Paul Coen; Nathan H Parker; Aasha I Hoogland; Brian D Gonzalez; Mary C Playdon; Steven Cole; Jennifer Ose; Yuichi Murayama; Erin M Siegel; Jane C Figueiredo; Heather S L Jim Journal: Cancers (Basel) Date: 2022-04-14 Impact factor: 6.575
Authors: Johanna Graf; Martin Teufel; Alexander Bäuerle; Peter Martus; Yesim Erim; Caterina Schug; Jana Heinen; Julia Barbara Krakowczyk; Jasmin Steinbach; Mirjam Damerau; Wolfgang Bethge; Andreas Dinkel; Sebastian Dries; Anja Mehnert-Theuerkauf; Anja Neumann; Dirk Schadendorf; Mitra Tewes; Jörg Wiltink; Alexander Wünsch; Stephan Zipfel Journal: BMJ Open Date: 2022-06-01 Impact factor: 3.006
Authors: Kelly A Hyland; Ashley M Nelson; Sarah L Eisel; Aasha I Hoogland; Javier Ibarz-Pinilla; Kendra Sweet; Paul B Jacobsen; Hans Knoop; Heather S L Jim Journal: Ann Behav Med Date: 2022-02-11
Authors: T A Kuut; F Müller; A Aldenkamp; E Assmann-Schuilwerve; A Braamse; S E Geerlings; K B Gibney; R A A Kanaan; P Nieuwkerk; T C Olde Hartman; D Pauëlsen; M Prins; K Slieker; M Van Vugt; C P Bleeker-Rovers; S P Keijmel; H Knoop Journal: Trials Date: 2021-12-02 Impact factor: 2.279
Authors: Laura B Oswald; Kelly A Hyland; Sarah L Eisel; Aasha I Hoogland; Hans Knoop; Ashley M Nelson; Javier Pinilla-Ibarz; Kendra Sweet; Paul B Jacobsen; Heather S L Jim Journal: Support Care Cancer Date: 2021-07-07 Impact factor: 3.359